Barely Significant
← all phrases

“a nonsignificant trend”

5,407 sentences · 5,407 papers · 7,516 search hits before verification · confirmed specimen

Sighted at

p<0.1

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

Both drugs were similar in terms of safety, although there was a nonsignificant trend toward a higher incidence of serious side effects with infliximab. 82 Kruh et al published the largest single-center retrospective, interventional, noncomparative cohort study evaluating the safety and efficacy of infliximab in various types of uveitis that failed to respond to other treatments.
This discrepancy may stem from several factors: (1) Patient and infection complexity: Randomized controlled trial (RCT) populations exhibit high heterogeneity, and the complexity of infections (such as endocarditis and deep-seated abscesses) far exceeds that of standardized laboratory models; (2) Suboptimal dosing regimens: The dosing regimens used in trials may fail to achieve the PK/PD targets required for synergy at the infection site; (3) Adverse events (AEs): The meta-analysis revealed a nonsignificant trend toward greater treatment discontinuation due to AEs in the combination arms, which may have potentially confounded the efficacy assessment.
Dividing the cohort into high and low ABL1/2 expression groups, tumors with high ABL1 expression showed a nonsignificant trend for worse overall survival (OS) in the SHH molecular subgroup ( Supplementary Figure 1A ), whereas tumors with high ABL2 expression showed a nonsignificant trend for worse overall survival in the SHH and group 3 molecular subgroups ( Supplementary Figure1B ).
Exploratory analyses showed that age, gender, viral hepatitis, and site of disease were not associated with PFS (data not shown); however, the 8 patients with conjunctival lesions as exclusive sites of disease showed a nonsignificant trend to better outcome, with a 5-year PFS of 88% (95% CI, 87%-89%) versus 59% (95% CI, 52%-65%) for the 20 patients with orbit lesions, associated or not with conjunctival infiltration ( Fig. 1 B).
Level 3 events (need for third-party assistance) are also important to quantify: in the current study, we did not evaluate this endpoint, but CGM-detected events <40 mg/dL, which would normally be associated with a level 3 presentation, were 5-fold reduced and reduction in time (minutes on CGM) spent <40 mg/dL showed a nonsignificant trend during the diurnal monitoring.
At 90 days, we observed a nonsignificant trend toward higher PPF rates among GLP-1RA users (OR: 1.65; 95% CI: 0.97–2.81), which progressed to a statistically significant elevation by 1 year (OR: 2.06; 95% CI: 1.17–3.62), driven primarily by TKA, with no clear effect in THA.